Skip to main content
SpringerLink
Log in

Management of Uterine Sarcomas

  • Chapter
Uterine Cancer

Part of the book series: Current Clinical Oncology ((CCO))

  • 503 Accesses

Abstract

Uterine sarcomas, including the subtypes leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma, are a heterogenous group of tumors which vary widely in their biology and prognosis. Surgery is the mainstay of treatment. The roles of chemotherapy, radiation therapy and hormonal therapy are poorly defined, in large part due to the rarity of these tumors. Prior clinical trials grouped uterine sarcomas together, which helped trial accrual but hampered applicability of trial results. Today’s trials are specific to each histology, and are often supplemented by molecular studies to improve interpretation of results. Continued investigations should point the way for future therapies directed towards these tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel R, et al. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.

    Article  PubMed  Google Scholar 

  2. Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956–1992: incidence, survival and mortality. Eur J Cancer. 1997;33(6):907–11.

    Article  CAS  PubMed  Google Scholar 

  3. Koivisto-Korander R, et al. Incidence of uterine leiomyosarcoma and endometrial stromal sarcoma in Nordic countries: results from NORDCAN and NOCCA databases. Maturitas. 2012;72:56–60.

    Article  CAS  PubMed  Google Scholar 

  4. Felix AS, et al. The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium. Br J Cancer. 2013;108:727–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. FIGO Committee on Gynecologic Oncology. FIGO staging for uterine sarcomas. Int J Gynecol Obstet. 2009;104:179.

    Article  Google Scholar 

  6. Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89:460–9.

    Article  PubMed  Google Scholar 

  7. Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 2000;88:2782–6.

    Article  CAS  PubMed  Google Scholar 

  8. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol. 1994;83(3):414–8.

    CAS  PubMed  Google Scholar 

  9. Goff BA, Rice LW, Fleischhacker D, et al. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol. 1993;50:105–9.

    Article  CAS  PubMed  Google Scholar 

  10. Kapp DS, et al. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008;112:820–30.

    Article  PubMed  Google Scholar 

  11. George S, et al. Retrospective cohort study evaluating the impact of intraperitoneal morcellation of outcomes of localized uterine leiomyosarcoma. Cancer. 2014;120:3154–8.

    Article  PubMed  Google Scholar 

  12. Park JY, et al. The impact of tumor morcellation during surgery on the prognosis of patients with apparent early uterine leiomyosarcoma. Gynecol Oncol. 2011;122:255–9.

    Article  PubMed  Google Scholar 

  13. Morice P, et al. Prognostic value of initial surgical procedure for patients with uterine sarcoma: analysis of 123 patients. Eur J Gynaecol Oncol. 2003;24:237–40.

    CAS  PubMed  Google Scholar 

  14. Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JLJR. Treatment of uterine leiomyosarcoma. Obstet Gynecol. 1988;71:845–50.

    CAS  PubMed  Google Scholar 

  15. Koontz JI, et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. PNAS. 2001;98:6348–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Micci F. Consistent rearrangement of chromosomal band 6p21 with generation of fusion genese JAZF1/PHF1 and EPC/PHF1 in endometrial stromal sarcoma. Cancer Res. 2006;66:107–12.

    Article  CAS  PubMed  Google Scholar 

  17. Chiang S, et al. Frequency of known gene rearrangements in endometrial stromal tumors. Am J Surg Pathol. 2011;35(9):1364–72.

    Article  PubMed  Google Scholar 

  18. Signorelli M, et al. Lymphadenectomy in uterine low-grade endometrial stromal sarcoma: an analysis of 19 cases and a literature review. Int J of Gynecol. Cancer. 2010;20(8):1363–6.

    Google Scholar 

  19. Barney B, et al. Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma? Int J Gynecol Cancer. 2009;19(7):1232–8.

    Article  PubMed  Google Scholar 

  20. Yoon A, et al. Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: a multicenter review of 114 cases. Gynecol Oncol. 2014;132:70–5.

    Article  PubMed  Google Scholar 

  21. Feng W, et al. Stage I to II WHO-2003 defined low-grade endometrial stromal sarcoma: how much primary therapy is needed and how little is enough? Int J Gynecol Cancer. 2013;23(3):488–93.

    Article  PubMed  Google Scholar 

  22. Shah JP, et al. Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol. 2008;112:1102–8.

    Article  PubMed  Google Scholar 

  23. Chan JK, et al. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer. 2008;99:1210–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Arend R, et al. Long-term outcome and natural history of uterine adenosarcomas. Gynecol Oncol. 2010;119:305–8.

    Article  PubMed  Google Scholar 

  25. Bernard B e. Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival. Gynecol Oncol. 2013;131:634–9.

    Article  PubMed  Google Scholar 

  26. Tanner EJ, et al. Management of uterine adenosarcomas with and without sarcomatous overgrowth. Gynecol Oncol. 2013;129:140–4.

    Article  PubMed  Google Scholar 

  27. Piscuoglio S, et al. Uterine adenosarcomas are mesenchymal neoplasms. J Pathol. 2016;238:381–8.

    Article  CAS  PubMed  Google Scholar 

  28. Soslow R, et al. Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases. Am J Surg Pathol. 2008;32(7):1013–21.

    Article  PubMed  Google Scholar 

  29. Michener C, Simon NL. Ovarian conservation in a woman of reproductive age with mullerian adenosarcoma. Gynecol Oncol. 2001;83:424–7.

    Article  CAS  PubMed  Google Scholar 

  30. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993;71:1702–9.

    Article  CAS  PubMed  Google Scholar 

  31. Ferrer F, Sabater S, Farrus B, et al. Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Group Oncologic Catala-Occita. Int J Radiat Oncol Biol Phys. 1999;44:47–52.

    Article  CAS  PubMed  Google Scholar 

  32. Sampath S, et al. The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys. 2010;76(3):728–34.

    Article  PubMed  Google Scholar 

  33. Magnuson WJ, et al. Impact of adjuvant pelvic radiotherapy in stage I uterine sarcoma. Anticancer Res. 2015;35(1):365–70.

    PubMed  Google Scholar 

  34. Mahdavi A, et al. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: A 20 year experience. Int J Gynecol Cancer. 2009;19:1080–4.

    Article  PubMed  Google Scholar 

  35. Reed NS, et al. Phase III randomized study to evaluate the role of adjuvant pelvic in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44:808–18.

    Article  CAS  PubMed  Google Scholar 

  36. Wright JD, et al. The role of radiation in improving survival for early stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol. 2008;199:536.e1–8.

    Article  Google Scholar 

  37. Weitmann HD, Knocke TH, Kucera H, Potter R. Radiation therapy in the treatment of endometrial stromal sarcoma. Int J Radiat Oncol Biol Phys. 2001;49(3):739–48.

    Article  CAS  PubMed  Google Scholar 

  38. Ricci S, et al. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma? Gynecol Oncol. 2013;131:629–33.

    Article  PubMed  Google Scholar 

  39. Mancari R, et al. Adjuvant chemotherapy in stage I – II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients. Gynecol Oncol. 2014;133:531–6.

    Article  CAS  PubMed  Google Scholar 

  40. Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 1985;3:1240–5.

    Article  CAS  PubMed  Google Scholar 

  41. Peters WA 3rd, Rivkin SE, Smith MR, Tesh DE. Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas and mixed mesodermal tumors. Gynecol Oncol. 1989;34:323–7.

    Article  PubMed  Google Scholar 

  42. Kushner DM, Webster KD, Belinson JL, Rybicki LA, Kennedy AW, Markman M. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. Gynecol Oncol. 2000;78:221–7.

    Article  CAS  PubMed  Google Scholar 

  43. van Nagell JR Jr, Hanson MB, Donaldson ES, Gallion HH. Adjuvant vincristine, dactinomycin, and cyclophosphamide therapy in stage I uterine sarcomas. A pilot study. Cancer. 1986;57:1451–4.

    Article  PubMed  Google Scholar 

  44. Hannigan EV, Freedman RS, Elder KW, Rutledge FN. Treatment of advanced uterine sarcoma with adriamycin. Gynecol Oncol. 1983;16:101–4.

    Article  CAS  PubMed  Google Scholar 

  45. Hannigan EV, Freedman RS, Elder KW, Rutledge FN. Treatment of advanced uterine sarcoma with vincristine, actinomycin D, and cyclophosphamide. Gynecol Oncol. 1983;15:224–9.

    Article  CAS  PubMed  Google Scholar 

  46. Pautier P, Rey A, Haie-Meder C, et al. Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone. Int J Gynecol Cancer. 2004;14:1112–7.

    Article  CAS  PubMed  Google Scholar 

  47. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a Phase II Trial. J Clin Oncol. 2002;20:2824–31.

    Article  CAS  PubMed  Google Scholar 

  48. Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109(3):329–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Hensley ML, et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer. 2013;119:1555–61.

    Article  CAS  PubMed  Google Scholar 

  50. Chu MC, Mor G, Lim C, Zheng W, Parkash V, Schwartz PE. Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol. 2003;90:170–6.

    Article  CAS  PubMed  Google Scholar 

  51. Wade K, Quinn MA, Hammond I, Williams K, Cauchi M. Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol Oncol. 1990;39:364–7.

    Article  CAS  PubMed  Google Scholar 

  52. Thanopoulou E, et al. Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital. Clin Sarcoma Res. 2015;5:8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Mizuno M, et al. Long-term medroxyprogesterone acetate therapy for low-grade endometrial stromal sarcoma. Int J Clin Oncol. 2012;17:348–54.

    Article  CAS  PubMed  Google Scholar 

  54. Spano JP, Soria JC, Kambouchner M, et al. Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med Oncol. 2003;20:87–93.

    Article  PubMed  Google Scholar 

  55. Maluf FC, Sabbatini P, Schwartz L, Xia J, Aghajanian C. Endometrial stromal sarcoma: objective response to letrozole. Gynecol Oncol. 2001;82:384–8.

    Article  CAS  PubMed  Google Scholar 

  56. Leunen M, Breugelmans M, De Sutter P, et al. Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol Oncol. 2004;95:769.

    Article  CAS  PubMed  Google Scholar 

  57. Mesia AF, Demopoulos RI. Effects of leuprolide acetate on low-grade endometrial stromal sarcoma. Am J Obstet Gynecol. 2000;182:1140–1.

    Article  CAS  PubMed  Google Scholar 

  58. Burt BM, et al. Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival. Ann Thorac Surg. 2011;92:1202–7.

    Article  PubMed  Google Scholar 

  59. Clavero JM. Gynecologic cancers: factors affecting survival after pulmonary metastasectomy. Ann Thorac Surg. 2006;81:2004–7.

    Article  PubMed  Google Scholar 

  60. Giuntoli R, et al. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol. 2007;106:82–8.

    Article  PubMed  Google Scholar 

  61. Leitao MM, et al. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol. 2002;87:287–94.

    Article  PubMed  Google Scholar 

  62. Leitao MM, et al. Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. Gynecol Oncol. 2012;125:409–13.

    Article  PubMed  Google Scholar 

  63. Spanos W, Guse C, Perez C, Grisby P, Doggett RL, Poulter C. Phase II study of multiple daily fractionations in the palliation of advanced pelvic malignancies: preliminary report of RTOG 8502. Int J Radiat Oncol Biol Phys. 1989;17:659–61.

    Article  PubMed  Google Scholar 

  64. Spanos WJ, et al. Late effect of multiple daily fraction palliation schedule for advanced pelvic malignancies (RTOG 8502). Int J Radiat Oncol Biol Phys. 1994;29(5):961–7.

    Article  PubMed  Google Scholar 

  65. Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983;52:626–32.

    Article  CAS  PubMed  Google Scholar 

  66. Muss HB, Bundy B, DiSaia PJ, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a Phase III trial of the Gynecologic Oncology Group). Cancer. 1985;55:1648–53.

    Article  CAS  PubMed  Google Scholar 

  67. Loehrer PJ, Sledge GW, Nicaise C, et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. J Clin Oncol. 1989;7:1655–9.

    Article  PubMed  Google Scholar 

  68. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11:1276–85.

    Article  CAS  PubMed  Google Scholar 

  69. Currie J, Blessing JA, Muss HB, Fowler J, Berman M, Burke TW. Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;61:27–30.

    Article  CAS  PubMed  Google Scholar 

  70. Piver MS, DeEulis TG, Lele SB, Barlow JJ. Cyclophosphamide, vincristine, adriamycin and dimethyl-triazeno imidazole carboxamide (CYVADIC) for sarcomas of the female genital track. Gynecol Oncol. 1982;14:319–23.

    Article  CAS  PubMed  Google Scholar 

  71. Pautier P, et al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS- 02): a non-randomised, multicenter, phase 2 trial. Lancet Oncol. 2015;16:457–64.

    Article  CAS  PubMed  Google Scholar 

  72. Hensley ML, et al. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first line treatment for metastatic uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 33:1180–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Pautier P et al. Randomized multicenter and stratified phase II study of Gemcitabine alone vs gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a federation nationale de Centres de Lutte Contre Le Cancer (FNCLCC) French Sarcoma Group (TAXOGEM) study.

    Google Scholar 

  74. Hadoux J, et al. Multimodal treatment with doxorubicin, cisplatin and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience. Int J Gynecol Cancer. 2015;25(2):296–302.

    Article  PubMed  Google Scholar 

  75. Sutton G, Blessing J, Hanjani P, Kramer P, Gynecologic Oncology Group. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;96:749–52.

    Article  CAS  PubMed  Google Scholar 

  76. Sutton GP, Blessing JA, Barrett RJ, McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol. 1992;166:556–9.

    Article  CAS  PubMed  Google Scholar 

  77. Look KY, Sandler A, Blessing JA, et al. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol. 2004;92:644–7.

    Article  CAS  PubMed  Google Scholar 

  78. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22:1480–90.

    Article  CAS  PubMed  Google Scholar 

  79. Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol. 2001;19:1248–55.

    Article  CAS  PubMed  Google Scholar 

  80. Thigpen T, Blessing JA, Beecham J, Homesley H, Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 1991;9:1962–6.

    Article  CAS  PubMed  Google Scholar 

  81. McMeekin DS, et al. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gyn Oncology. 2007;106(3):596–603.

    Article  CAS  Google Scholar 

  82. Duska LR, et al. A phase II evaluation of ixabepilone in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study. Gyn Oncology. 2014;135:44–8.

    Article  CAS  Google Scholar 

  83. Hensley ML, et al. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study. Gyn Oncology. 2009;115:460–5.

    Article  CAS  Google Scholar 

  84. Gremel G, et al. A prognosis based classification of undifferentiated uterine sarcomas: identification of mitotic index, hormone receptors and YWHAE-FAM22 translocation status as predictors of survival. Int J Cancer. 2015;136(7):1608–18.

    Article  CAS  PubMed  Google Scholar 

  85. Lee CH, et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high grade and clinically aggressive tumor. Am J Surg Pathol. 2012;36(5):641–53.

    Article  PubMed  Google Scholar 

  86. Lee CH, et al. Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol. 2012;36(10):1562–70.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Malouf GG, et al. Prognostic factors and outcome of undifferentiated endometrial sarcoma treated by multimodal therapy. Int J Gynecol Obset. 2013;122(1):57–61.

    Article  Google Scholar 

  88. Tanner EJ, et al. High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol Oncol. 2012;127:27–31.

    Article  PubMed  Google Scholar 

  89. Sutton G, Blessing JA, Park R, DiSaia PJ, Rosenshein N. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. Obstet Gynecol. 1996;87:747–50.

    Article  CAS  PubMed  Google Scholar 

  90. Lin YC, Kudelka AP, Tresukosol D, et al. Prolonged stabilization of progressive endometrial stromal sarcoma with prolonged oral etoposide therapy. Gyencol Oncol. 1995;58:262–5.

    Article  CAS  Google Scholar 

  91. Takano T, et al. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma in undifferentiated endometrial sarcoma in Japan. Int J Clin Oncol. 2014;19:897–905.

    Article  CAS  PubMed  Google Scholar 

  92. Kalender ME, et al. Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low grade endometrial stromal sarcoma. Cancer Chemother Parmacol. 2009;63(3):555–9.

    Article  Google Scholar 

  93. Amant F, et al. Gynecologic Cancer InterGroup consensus review for endometrial stromal sarcoma. Int J Gynecol Cancer. 2014;24(9):S67–72.

    Article  PubMed  Google Scholar 

  94. Rauh-Hain JA, et al. Endometrial stromal sarcoma: a systematic review. Obstet Gynecol. 2013;122:676–83.

    Article  PubMed  Google Scholar 

  95. Tanz R, et al. Endometrial stromal sarcoma: prognostic factors and impact of adjuvant therapy in early stages. Hematol Oncol Stem Cell Ther. 2012;5(1):31–5.

    Article  CAS  PubMed  Google Scholar 

  96. Leitao MM, Soslow RA, Nonaka D, et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer. 2004;101:1455–62.

    Article  CAS  PubMed  Google Scholar 

  97. O’Cearbhaill R, et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol. 2010;116:424–9.

    Article  PubMed  CAS  Google Scholar 

  98. George et al. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer. 2014;120:738–43.

    Article  CAS  Google Scholar 

  99. Mackay HJ, Buckanovich RJ, Hirte H, et al. A phase II study of single agent aflibercept (VEGF trap) in metastatic gynecologic carcinosarcomas and uterine leiomyosarcomas: a trial of the Princess Margaret Hospital, Chicago and Californai Cancer Consortia. Gynecol Oncol. 2012;125:136–40.

    Article  CAS  PubMed  Google Scholar 

  100. Cheng X, et al. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol. 2011;121:323–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, NYU School of Medicine, New York, NY, USA

    Leslie R. Boyd

Authors
  1. Leslie R. Boyd
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leslie R. Boyd .

Editor information

Editors and Affiliations

  1. NYU Langone Medical Center, New York, NY, USA

    Franco Muggia

  2. Division of Gynecologic Oncology, Yale University, Yale School of Medicine, New Haven, CT, USA

    Alessandro D. Santin

  3. Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

    Esther Oliva (Professor of Pathology) (Professor of Pathology)

  4. Harvard Medical School, Boston, MA, USA

    Esther Oliva (Professor of Pathology) (Professor of Pathology)

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Boyd, L.R. (2016). Management of Uterine Sarcomas. In: Muggia, F., Santin, A.D., Oliva, E. (eds) Uterine Cancer. Current Clinical Oncology. Springer, Cham. https://doi.org/10.1007/7631_2016_13

Download citation

  • DOI: https://doi.org/10.1007/7631_2016_13

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-47267-6

  • Online ISBN: 978-3-319-47269-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation